Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD.

ABSTRACT:

Purpose

To describe the adverse events associated with brolucizumab, in particular the sequence of intraocular inflammation (IOI), retinal vasculitis (RV), and/or retinal vascular occlusion (RO).

Methods

This was an unmasked post hoc analysis of the randomized HAWK/HARRIER clinical trials. Patients with neovascular AMD in the brolucizumab arms of the trials were included. IOI-related adverse events reported by study investigators were analyzed to determine early signs and the time course of IOI-related adverse events, using a subgroup of patients with definite/probable IOI cases identified in an independent unmasked post hoc review by an external safety review committee. A limited literature review on IOI following anti-VEGF therapy was also conducted.

Results

Among 5

SUBMITTER: Khoramnia R 

PROVIDER: S-EPMC9061681 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature